Nuvation Bio Inc

NYSE:NUVBUnited States

Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.

Contact Information

Headquarters

357 Tehama Street, Floor 3SAN FRANCISCO, CA, United States 94103

Phone

415-754-3517

Fax

302-636-5454

Executives

President, Chief Executive Officer, Founder, Director

David Hung

Chief Financial Officer and Principal Financial Officer

Philippe Sauvage

Chief Executive Officer of AnHeart Therapeutics and Director

Junyuan Wang

Chief People Officer

Stacy Markel

Principal Accounting Officer, Vice President - Finance

Moses Makunje